# | Title | Journal | Year | Citations |
---|
1 | A Review of the Pharmacological and Clinical Profile of Mirtazapine | CNS Neuroscience & Therapeutics | 2001 | 494 |
2 | Paracetamol: New Vistas of an Old Drug | CNS Neuroscience & Therapeutics | 2006 | 460 |
3 | Paroxetine: A Review | CNS Neuroscience & Therapeutics | 2001 | 352 |
4 | Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597) | CNS Neuroscience & Therapeutics | 2006 | 331 |
5 | The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease | CNS Neuroscience & Therapeutics | 2003 | 328 |
6 | Neuroprotective Effects of Edaravone: a Novel Free Radical Scavenger in Cerebrovascular Injury | CNS Neuroscience & Therapeutics | 2006 | 324 |
7 | Lacosamide: A Review of Preclinical Properties | CNS Neuroscience & Therapeutics | 2007 | 316 |
8 | Valproate: Past, Present, and Future | CNS Neuroscience & Therapeutics | 2003 | 274 |
9 | Galantamine — a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer's Disease | CNS Neuroscience & Therapeutics | 2002 | 236 |
10 | Piracetam: A Review of Pharmacological Properties and Clinical Uses | CNS Neuroscience & Therapeutics | 2005 | 218 |
11 | Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use Cessation Agent | CNS Neuroscience & Therapeutics | 2006 | 217 |
12 | BMS‐204352: A Potassium Channel Opener Developed for the Treatment of Stroke | CNS Neuroscience & Therapeutics | 2002 | 201 |
13 | Moclobemide: Therapeutic Use and Clinical Studies | CNS Neuroscience & Therapeutics | 2003 | 184 |
14 | The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile | CNS Neuroscience & Therapeutics | 2004 | 184 |
15 | Guanfacine and Guanfacine Extended Release: Treatment for ADHD and Related Disorders | CNS Neuroscience & Therapeutics | 2007 | 183 |
16 | The Antidepressant and Antiinflammatory Effects of Rolipram in the Central Nervous System | CNS Neuroscience & Therapeutics | 2001 | 178 |
17 | Phenibut (β‐Phenyl‐GABA): A Tranquilizer and Nootropic Drug | CNS Neuroscience & Therapeutics | 2001 | 173 |
18 | SCH 23390: The First Selective Dopamine D1‐Like Receptor Antagonist | CNS Neuroscience & Therapeutics | 2001 | 172 |
19 | Catechol‐O‐methyltransferase and Its Inhibitors in Parkinson's Disease | CNS Neuroscience & Therapeutics | 2007 | 166 |
20 | Metabotropic Glutamate Receptor Subtype 5 Antagonists MPEP and MTEP | CNS Neuroscience & Therapeutics | 2006 | 149 |
21 | A New Look at the 5?-Reductase Inhibitor Finasteride | CNS Neuroscience & Therapeutics | 2006 | 146 |
22 | Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology | CNS Neuroscience & Therapeutics | 2004 | 133 |
23 | Ginsenosides: Are Any of them Candidates for Drugs Acting on the Central Nervous System? | CNS Neuroscience & Therapeutics | 2007 | 132 |
24 | Ondansetron: A Selective 5‐HT3 Receptor Antagonist and Its Applications in CNS‐Related Disorders | CNS Neuroscience & Therapeutics | 2001 | 128 |
25 | Therapeutic Potential of Wogonin: A Naturally Occurring Flavonoid | CNS Neuroscience & Therapeutics | 2005 | 128 |
26 | The Pharmacology of Physostigmine | CNS Neuroscience & Therapeutics | 1998 | 127 |
27 | NAP: Research and Development of a Peptide Derived from Activity-Dependent Neuroprotective Protein (ADNP) | CNS Neuroscience & Therapeutics | 2005 | 127 |
28 | Xanomeline and the Antipsychotic Potential of Muscarinic Receptor Subtype Selective Agonists | CNS Neuroscience & Therapeutics | 2003 | 122 |
29 | Involvement of Calpain Activation in Neurodegenerative Processes | CNS Neuroscience & Therapeutics | 2006 | 117 |
30 | Retigabine: Chemical Synthesis to Clinical Application | CNS Neuroscience & Therapeutics | 2005 | 115 |
31 | Pharmacology of Flibanserin | CNS Neuroscience & Therapeutics | 2002 | 114 |
32 | Role of Hyperforin in the Pharmacological Activities of St. John's Wort | CNS Neuroscience & Therapeutics | 2004 | 114 |
33 | A New Look at the Respiratory Stimulant Doxapram | CNS Neuroscience & Therapeutics | 2006 | 114 |
34 | Augmentation Treatment of Psychotherapy for Anxiety Disorders with D-Cycloserine | CNS Neuroscience & Therapeutics | 2006 | 111 |
35 | Ethosuximide: From Bench to Bedside | CNS Neuroscience & Therapeutics | 2007 | 111 |
36 | Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature | CNS Neuroscience & Therapeutics | 2004 | 110 |
37 | A Review of the Properties of Spiradoline: A Potent and Selective k‐Opioid Receptor Agonist | CNS Neuroscience & Therapeutics | 2003 | 108 |
38 | TC‐1734: An Orally Active Neuronal Nicotinic Acetylcholine Receptor Modulator with Antidepressant, Neuroprotective and Long‐Lasting Cognitive Effects | CNS Neuroscience & Therapeutics | 2004 | 104 |
39 | The Pharmacology of CP‐154,526, a Non‐Peptide Antagonist of the CRH1 Receptor: A Review | CNS Neuroscience & Therapeutics | 2003 | 100 |
40 | Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory Diseases | CNS Neuroscience & Therapeutics | 2007 | 98 |
41 | Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake Inhibitor | CNS Neuroscience & Therapeutics | 2006 | 97 |
42 | Pharmacological Actions of NGB 2904, a Selective Dopamine D 3 Receptor Antagonist, in Animal Models of Drug Addiction | CNS Neuroscience & Therapeutics | 2007 | 96 |
43 | S 17092: A Prolyl Endopeptidase Inhibitor as a Potential Therapeutic Drug for Memory Impairment. Preclinical and Clinical Studies | CNS Neuroscience & Therapeutics | 2002 | 95 |
44 | Pharmacological Profile of Huperzine A, a Novel Acetylcholinesterase Inhibitor from Chinese Herb | CNS Neuroscience & Therapeutics | 1999 | 94 |
45 | Levetiracetam: Part II, the Clinical Profile of a Novel Anticonvulsant Drug | CNS Neuroscience & Therapeutics | 2007 | 91 |
46 | Pharmacological Properties, Central Nervous System Effects, and Potential Therapeutic Applications of Atipamezole, a Selective α2‐Adrenoceptor Antagonist | CNS Neuroscience & Therapeutics | 2005 | 90 |
47 | Bryostatin-1: Pharmacology and Therapeutic Potential as a CNS Drug | CNS Neuroscience & Therapeutics | 2006 | 89 |
48 | UFP‐101, a Peptide Antagonist Selective for the Nociceptin/Orphanin FQ Receptor | CNS Neuroscience & Therapeutics | 2005 | 88 |
49 | Pharmacology of the β‐Carboline FG‐7142, a Partial Inverse Agonist at the Benzodiazepine Allosteric Site of the GABAA Receptor: Neurochemical, Neurophysiological, and Behavioral Effects | CNS Neuroscience & Therapeutics | 2007 | 87 |
50 | 2,3-Benzodiazepines (GYKI 52466 and Analogs): Negative Allosteric Modulators of AMPA Receptors | CNS Neuroscience & Therapeutics | 1996 | 85 |